The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
Recruiting now · Not applicable
Conditions studied: Kidney Failure, Acute, Myopathy; Drugs, Heart Arrhythmia, Succinylcholine Sensitivity, Muscle Relaxation, General Anesthetic Drug Adverse Reaction, Projection
In brief
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Key facts
- Study ID
- NCT06707532
- Run by
- 4th Military Clinical Hospital with Polyclinic, Poland
- People needed
- 32
- Starts
- 2024-08-01
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2024-11-27
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation
You may not qualify if…
- Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.
Where it is running
- 4th Military Clinical Hospital with Polyclinic — Wroclaw, Lower Silesian Voivodeship, Poland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.